Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), BeOne Medicines (ONC)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), BeOne Medicines (ONC – Research Report) and CG Oncology, Inc. (CGON – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rhythm Pharmaceuticals (RYTM)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $131.00. The company’s shares closed last Friday at $92.73.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of
Currently, the analyst consensus on Rhythm Pharmaceuticals is a Strong Buy with an average price target of $141.36, implying a 46.2% upside from current levels. In a report issued on February 18, RBC Capital also initiated coverage with a Buy rating on the stock with a $145.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
BeOne Medicines (ONC)
CMB International Securities analyst Jill Wu maintained a Buy rating on BeOne Medicines today and set a price target of $392.43. The company’s shares closed last Friday at $316.99.
According to TipRanks.com, Wu is a 5-star analyst with an average return of
Currently, the analyst consensus on BeOne Medicines is a Strong Buy with an average price target of $408.49, implying a 28.2% upside from current levels. In a report issued on February 26, TipRanks – OpenAI also upgraded the stock to Buy with a $387.00 price target.
CG Oncology, Inc. (CGON)
RBC Capital analyst Leonid Timashev maintained a Buy rating on CG Oncology, Inc. on February 27 and set a price target of $73.00. The company’s shares closed last Friday at $58.80.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CG Oncology, Inc. with a $83.27 average price target, representing a 49.3% upside. In a report issued on February 13, Piper Sandler also maintained a Buy rating on the stock with a $70.00 price target.
